• 1
    Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann. Intern. Med. 1996; 124: 654663.
  • 2
    Liu Z, Cumberland WG, Hltin LE, Kaplan AH, Detels R, Giorgi JV. CD8+ T-lymphocytes activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J. Acquir. Immune. Defic. Syndr. 1998; 18: 332340.
  • 3
    Giorgi JV, Hultin LE, McKeating JA et al. Shorter survival in advanced human immunodeficiency virus Type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 1999; 179: 859870.
  • 4
    Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretrioviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112116.
  • 5
    Lykersos CG, Hoover DR, Guccione M et al. Changes in depressive symptoms as AIDS develops. Am. J. Psychiatry 1996; 153: 14301437.
  • 6
    Leserman J, Petitto JM, Perkins DO, Folds JD, Golden RN, Evans DL. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus infected men. Arch. Gen. Psychiatry 1997; 54: 279285.
  • 7
    Leserman J, Petitto JM, Golden RN et al. Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS. Am. J. Psychiatry 2000; 157: 12211228.
  • 8
    Leserman J, Petitto JM, Gu H et al. Progression to AIDS, a clinical AIDS condition, and mortality: psychosocial and physiological predictors. Psychol. Med. 2002; 32: 10591073.
  • 9
    Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol. Psychiatry 2003; 54: 295306.
  • 10
    Cruess DG, Petitto JM, Leserman J et al. Depression and HIV infection: impact on immune function and disease progression. CNS Spectr. 2003; 8: 5258.
  • 11
    Maes M, Lambrechts J, Bosmans E et al. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody. Psychol. Med. 1992; 22: 4553.
  • 12
    Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995; 20: 111116.
  • 13
    Maes M, Bosmans E, Jongh RD, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853858.
  • 14
    Schleifer SJ, Keller SE, Bartlett JA. Depression and immunity: clinical factors and therapeutic course. Psychiatry Res. 1999; 85: 6369.
  • 15
    Stern RA, Singer NG, Silva SG et al. Neurobehavioral functioning in a nonconfounded group of asymptomatic HIV-seropositive homosexual men. Am. J. Psychiatry 1992; 149: 877906.
  • 16
    Perkins DO, Stern RA, Golden RN, Murphy C, Naftolowitz D, Evans DL. Mood disorders in HIV infection: prevalence and risk factors in a non-epicenter of the AIDS epidemic. Am. J. Psychiatry 1994; 151: 233236.
  • 17
    Lipsitz JD, Williams JB, Rabkin JG et al. Psychopathology in male and female intravenous drug user with and without HIV infection. Am. J. Psychiatry 1994; 151: 16621668.
  • 18
    Atkinson JJ, Grant I, Kennedy CJ, Richman DD, Spector SA, McCutchan JA. Prevalence of psychiatric disorders among men infected with human immunodeficiency virus: a controlled study. Arch. Gen. Psychiatry 1988; 45: 859864.
  • 19
    Bing EG, Burnam MA, Longshore D et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch. Gen. Psychiatry 2001; 58: 721728.
  • 20
    Cruess DG, Evans DL, Repetto MJ, Gettes D, Douglas SD, Petitto JM. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol. Psychiatry 2003; 54: 307316.
  • 21
    Rabkin JG, Ferrando SJ, Jacobsberg LB, Fishman B. Prevalence of axis I disorders in an AIDS cohort: a cross-sectional, controlled study. Compr. Psychiatry 1997; 38: 146154.
  • 22
    Bear JW. Study of 60 patients with AIDS or AIDS-related complex requiring psychiatric hospitalization. Am. J. Psychiatry 1989; 146: 12851288.
  • 23
    Snyder S, Reyner A, Schmeidler Bogursky E, Gomez H, Strain JJ. Prevalence of mental disorders in newly admitted medical inpatients with AIDS. Psychosomatics 1992; 33: 166170.
  • 24
    Huang TL, Leu HS. Psychiatric characteristics of HIV-infected patients with cocktail therapy. Taiwanese J. Psychiatry 2000; 14: 125131 (in Chinese).
  • 25
    Perkins DO, Leserman J, Stern RA et al. Somatic symptoms and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Am. J. Psychiatry 1995; 152: 17761781.
  • 26
    Griffin KW, Rabkin JG, Remien RH, Williams JBW. Disease severity, physical limitations and depression in HIV-infected men. J. Psychosom. Res. 1997; 44: 219227.
  • 27
    Kalichman SC, Rompa D, Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. J. Nerv. Ment. Dis. 2000; 188: 662670.
  • 28
    Evans DL, Ten Have TR, Douglas SD et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am. J. Psychiatry 2002; 159: 17521759.
  • 29
    Cole SW, Kemeny ME, Fahey JL, Zack JA, Naliboff BD. Psychological risk factors for HIV pathogenesis: mediation by the autonomic nervous system. Biol. Psychiatry 2003; 54: 14441456.
  • 30
    Centers for Disease Control 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. M.M.W.R. 41 (RR-17), 1–19.
  • 31
    First MB, Spitzer RL, Gibbon M, Williams JBW. User’s Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version. American Psychiatric Press, Washington DC, 1997.
  • 32
    Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 1967; 6: 278296.
  • 33
    Evans DL, Leserman J, Perkins DO et al. Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in asymptomatic HIV infection. Am. J. Psychiatry 1995; 152: 543550.
  • 34
    Ho HN, Hultin LE, Mitsuyasu RT et al. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J. Immunol. 1993; 150: 30703079.
  • 35
    Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP. Treatment of depression is associated with suppression of nonspecific Th1 responses in multiple sclerosis. Arch. Neurol. 2001; 58: 10811086.
  • 36
    Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav. Immun. 2001; 15: 724.
  • 37
    DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001; 15: 12811285.
  • 38
    Elliot AJ, Karina KK, Bergam K, Russo J, Claypoole K, Roy-Byme PP. Randomized, placebo-controlled trial of paroxetine versus immipramine in depressed HIV-positive outpatients. Am. J. Psychiatry 1998; 155: 367372.
  • 39
    Ferrando SJ, Rabkin JG, De Moore GM, Rabkin R. Antidepressant treatment of depression in HIV-seropositive women. J. Clin. Psychiatry 1999; 60: 741746.
  • 40
    Rabkin JG, Rabkin R, Harrison W, Wagner G. Effect of immipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am. J. Psychiatry 1994; 151: 516523.
  • 41
    Rabkin JG, Wagner G, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS. A randomized, placebo-controlled trial. Am. J. Psychiatry 1999; 156: 101107.